Quick Comparison
| NN1706 | Semaglutide | |
|---|---|---|
| Half-Life | Approximately 14-18 hours, supporting once-daily dosing | 168 hours (7 days) |
| Typical Dosage | Phase 1 trials: stepwise dose escalation from low microgram doses up to multiple milligrams subcutaneous once daily. Optimal dosing for Phase 2/3 still being established. Daily dosing allows tighter dose adjustment than weekly drugs, at the cost of injection burden. | Weight management (Wegovy): 0.25 mg subcutaneous once weekly, escalating over 16 weeks to 2.4 mg once weekly. Diabetes (Ozempic): 0.25 mg subcutaneous once weekly, escalating to 1-2 mg once weekly. Oral (Rybelsus): 3 mg once daily for 30 days, then 7-14 mg once daily on an empty stomach. |
| Administration | Subcutaneous injection (once daily) | Subcutaneous injection (weekly). Oral formulation available (Rybelsus). |
| Research Papers | 1 papers | 30 papers |
| Categories |
Mechanism of Action
NN1706
NN1706 is a once-daily GLP-1/GIP/glucagon triple receptor agonist — Novo Nordisk's mechanistic equivalent to Eli Lilly's retatrutide, designed to activate all three pathways simultaneously in a single molecule. Each receptor contributes complementary metabolic effects: GLP-1 agonism centrally suppresses appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion; GIP agonism augments insulin response and modulates adipose lipid handling; and glucagon receptor agonism in the liver drives fatty acid oxidation, ketogenesis, and hepatic glucose output, while in brown and beige adipose tissue it promotes thermogenesis and increases whole-body energy expenditure.
The key engineering challenge in any glucagon-containing multi-agonist is balancing glucagon's hyperglycemic tendency against the glucose-lowering effect of GLP-1 and GIP. NN1706's receptor potency ratios are tuned so that incretin-driven insulinotropic effects sufficiently offset glucagon-driven glucose production, producing net glycemic improvement alongside enhanced fat oxidation. The glucagon component is what differentiates triple agonists like NN1706 and retatrutide from dual GLP-1/GIP agonists like tirzepatide — the additional energy-expenditure and hepatic-fat-mobilising effects of glucagon are the main reason triple agonists have produced higher weight-loss numbers in early trials.
The pharmacokinetic profile gives NN1706 a half-life of roughly 14-18 hours, matched to once-daily subcutaneous dosing rather than the once-weekly schedule of retatrutide. The trade-off is more injections per week against tighter dose control, smoother plasma concentrations, and faster ability to adjust or pause dosing if side effects emerge. The first human data published in 2026 from Phase 1 trials in rodents, monkeys, and humans showed meaningful weight loss with an acceptable initial tolerability profile, setting up Phase 2 obesity and type 2 diabetes trials.
Semaglutide
Semaglutide is a modified version of the natural incretin hormone GLP-1, engineered with 94% structural homology to the native peptide. It binds to GLP-1 receptors expressed throughout the body, triggering a cascade of metabolic effects. In the pancreas, it stimulates glucose-dependent insulin secretion from beta cells while suppressing glucagon release from alpha cells, providing dual glycemic control that only activates when blood sugar is elevated.
In the central nervous system, semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamic arcuate nucleus and the brainstem's nucleus tractus solitarius. This suppresses appetite by modulating POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) neuronal pathways. The result is a significant reduction in hunger, food cravings, and caloric intake — patients typically experience a fundamental shift in their relationship with food.
The extended duration of action comes from a C18 fatty di-acid chain attached at position 26 (lysine), which enables strong non-covalent binding to circulating albumin. This albumin binding shields semaglutide from DPP-4 enzymatic degradation — the process that destroys native GLP-1 within minutes — extending its half-life to approximately 7 days. Additionally, semaglutide slows gastric emptying through vagal nerve signaling, contributing to post-meal satiety and reduced glycemic excursions.
Risks & Safety
NN1706
Common
nausea, vomiting, diarrhea, decreased appetite (similar to other GLP-1 class drugs). Daily dosing produces more even side-effect profile vs weekly peaks but requires daily injections.
Serious
pancreatitis, gallstones, slightly elevated heart rate (signal seen with other glucagon-receptor-active drugs).
Rare
thyroid C-cell tumour class warning, severe allergic reactions. Limited human safety data so far.
Semaglutide
Common
nausea (30-45% of users), vomiting, diarrhea, constipation, stomach pain, headache.
Serious
inflammation of the pancreas (pancreatitis), gallstones, kidney problems from dehydration, loss of muscle mass alongside fat.
Rare
thyroid tumours seen in animal studies, severe allergic reactions.
Full Profiles
NN1706 →
Novo Nordisk's answer to retatrutide — a once-daily injection that activates all three of the major appetite and metabolism hormones (GLP-1, GIP, and glucagon). The first human data was published in 2026, showing meaningful weight loss in obese subjects and confirming the daily-dosing mechanism is tolerable. Direct competitor to Lilly's once-weekly retatrutide, with the trade-off of more frequent dosing in exchange for potentially smoother side-effect control and easier dose adjustment.
Semaglutide →
The most widely prescribed weight loss medication in the world, sold as Wegovy and Ozempic. Works by dramatically reducing appetite and food cravings — most people report feeling full much faster and losing interest in snacking. In clinical trials, patients lost an average of 15-17% of their body weight. Also available as a daily pill (Rybelsus). Originally developed for type 2 diabetes, it also helps control blood sugar levels.